PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

623 articles indexed across 24 specialties, each reviewed by a licensed pharmacist before publication.

Showing 67 from 1 topic.Sort: Newest | Oldest
Emerging Pharmacotherapy Landscape for MASLD and MASH
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Also in Gastroenterology / Hepatology

Innovative treatments for MASLD target diverse pathways.

Incretin Therapies Reshape Post-Bariatric Weight Recurrence Management
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low

Incretin-based therapies redefine post-bariatric weight management.

Anti-Obesity Drugs and Female Reproductive Dysfunction: A Mechanistic Review
Analysis Women's Health / Reproductive Hypothesis-generating Grade: Low
Also in Endocrinology / Diabetes / Obesity

Anti-obesity drugs show promise for enhancing reproductive health in obese women.

Pharmacotherapy Reshapes Obstructive Sleep Apnea Management Toward Endotype-Driven Care
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Also in Pulmonology / Respiratory

New drug options show promise for improving sleep apnea treatment beyond CPAP.

Sitagliptin Beats Pioglitazone for Stringent HbA1c Targets in Triple Therapy
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low

Sitagliptin outperforms pioglitazone in metabolic outcomes for T2DM.

DOACs Outperform Warfarin for VTE in Morbid Obesity
Analysis Anticoagulation / Hematology Confirmatory Grade: Low
Also in Endocrinology / Diabetes / Obesity

DOACs might outperform warfarin for VTE in morbid obesity.

Network meta-analysis ranks once-weekly GLP-1 agonists by efficacy and tolerability
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate

Tirzepatide outshines in efficacy but watch for side effects.

Pharmacist-Led Remote Diabetes Care Linked to Better Glycemic Control
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Also in Ambulatory Care / MTM, Clinical Practice

Remote pharmacist-led interventions improve outcomes in type 2 diabetes mellitus.

Early Combination Cardiorenal Therapy in Diabetic Kidney Disease
★ Must Read Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Also in Nephrology

Combining therapies transforms outcomes in diabetes-related kidney disease.

Deintensification Doubled But Still Lags in Overtreated Older Diabetics
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Also in Geriatrics

Exploring medication changes for older adults with diabetes.

Tirzepatide Beats Dulaglutide on Cardiorenal Outcomes in Real-World HFpEF
★ Editor's Pick Analysis Cardiology Hypothesis-generating Grade: Low
Also in Endocrinology / Diabetes / Obesity

Tirzepatide outperforms dulaglutide in cardiorenal protection for HFpEF.

Perceived Competence Separates GLP-1RA Weight Management Trajectories
Analysis Endocrinology / Diabetes / Obesity Hypothesis-generating Grade: Low
Also in Ambulatory Care / MTM

Patient competence levels influence success with GLP-1 therapy for weight loss.

GLP-1 Receptor Agonists Show No Excess Bowel Obstruction Risk
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Also in Gastroenterology / Hepatology, Medication Safety

GLP-1 receptor agonists show no increased bowel obstruction risk compared to SGLT2 inhibitors.

SGLT2 Inhibitors Show No Significant Serious UTI Excess
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Also in Infectious Disease / Antimicrobials

SGLT2 inhibitors show no significant rise in UTI risk.

Second-Line Agents Delay Insulin Versus Secretagogues in Type 2 Diabetes
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low

Second-line antidiabetic drugs play a key role in delaying insulin therapy.